17-553 Phase I
A Phase 1 Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects with Advanced Cancers (View details on clinicaltrial.gov)
Search Cancer Clinical Trials
The Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
15 results
20-001 Phase I
A Phase 1, Multicenter, Open-Label Study of CC-97540, CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (View details on clinicaltrial.gov)
15-404 Phase I
A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) (View details on clinicaltrial.gov)
19-877 Phase I
A Phase 1, Open-label, Multicenter Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (KarMMa-4) (View details on clinicaltrial.gov)
19-477 Phase II
A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR T cells in subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma (View details on clinicaltrial.gov)
20-152 Phase II
A Phase 2 Study of Donor-Derived Multi-Tumor-Associated Antigen-Specific T Cells (MT-401) Administered to Patients with Acute Myeloid Leukemia (AML) following Hematopoietic Stem Cell Transplantation (View details on clinicaltrial.gov)
18-604 Phase II
A Phase 2, Multicohort, Open-label, Multicenter Study to Determine the Efficacy and Safety of bb2121 in Subjects with Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma Having Progressed Within One Year of Initial Treatment (KarMMa-2). (View details on clinicaltrial.gov)
20-011 Phase II
A Phase 2, Open-Label, Single-Arm, Multicohort, Multicenter Trial To Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) (TRANSCEND FL) (View details on clinicaltrial.gov)
19-797 Phase II
A Phase 2, Single-Arm, Open-Label Study of Itacitinib, for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy (View details on clinicaltrial.gov)
17-033 Phase I
A Phase I Open Label, Clinical Trial Evaluating the Safety and Anti-tumor Activity of Autologous T Cells Expressing Enhanced TCRs Specific for Alpha-fetoprotein (AFPc332T) in HLA-A2 Positive Subjects with Advanced Hepatocellular Carcinoma (HCC) (View details on clinicaltrial.gov)
Showing 1 - 10 of 15 results